MersV1, PascalFrancis, Curation, bibRecord, 000105

Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment

Identifieur interne : 000105 ( PascalFrancis/Curation ); précédent : 000104; suivant : 000106

Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment

Auteurs : J. Lisziewicz [États-Unis] ; D. Sun [États-Unis] ; M. Klotman [États-Unis] ; S. Agrawal ; P. Zamecnik ; R. Gallo [États-Unis]

Source :

Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 1992.

RBID : Pascal:93-0236257

Descripteurs français

Pascal (Inist)
- Virus HIV1, Antiviral, Inhibition, Infection, Modèle, Replication in vitro, Immunodéficit acquis syndrome, Spécificité, Séquence nucléotide, Chimiothérapie, Traitement, In vitro, Synthèse chimique, Mécanisme action, Lignée MOLT3, DNA antisens.

English descriptors

KwdEn :
- AIDS, Antisense DNA, Antiviral, Chemical synthesis, Chemotherapy, HIV-1 virus, In vitro, In vitro replication, Infection, Inhibition, Mechanism of action, Models, Nucleotide sequence, Specificity, Treatment.

Abstract

We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) injection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 μM concentration. Variations in antiviral activity were seen among the different oligonucleotides, invealing an effect of target selection

A01	`01`	`1`		`@0 0027-8424`
A02	`01`			`@0 PNASA6`
A03		`1`		`@0 Proc. Natl. Acad. Sci. U. S. A.`
A05				`@2 89`
A06				`@2 23`
A08	`01`	`1`	`ENG`	`@1 Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment`
A11	`01`	`1`		`@1 LISZIEWICZ (J.)`
A11	`02`	`1`		`@1 SUN (D.)`
A11	`03`	`1`		`@1 KLOTMAN (M.)`
A11	`04`	`1`		`@1 AGRAWAL (S.)`
A11	`05`	`1`		`@1 ZAMECNIK (P.)`
A11	`06`	`1`		`@1 GALLO (R.)`
A14	`01`			`@1 NIH, national cancer inst., lab. tumor cell biology @2 Bethesda MD 20892 @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 6 aut.`
A20				`@1 11209-11213`
A21				`@1 1992`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 574 @5 354000032371390230`
A44				`@0 0000`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 93-0236257`
A60				`@1 P`
A61				`@0 A`
A64		`1`		`@0 Proceedings of the National Academy of Sciences of the United States of America`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) injection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 μM concentration. Variations in antiviral activity were seen among the different oligonucleotides, invealing an effect of target selection
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Virus HIV1 @2 NW`
C03	`01`	`X`	`ENG`	`@0 HIV-1 virus @2 NW`
C03	`01`	`X`	`SPA`	`@0 HIV-1 virus @2 NW`
C03	`02`	`X`	`FRE`	`@0 Antiviral`
C03	`02`	`X`	`ENG`	`@0 Antiviral`
C03	`02`	`X`	`SPA`	`@0 Antiviral`
C03	`03`	`X`	`FRE`	`@0 Inhibition`
C03	`03`	`X`	`ENG`	`@0 Inhibition`
C03	`03`	`X`	`SPA`	`@0 Inhibición`
C03	`04`	`X`	`FRE`	`@0 Infection`
C03	`04`	`X`	`ENG`	`@0 Infection`
C03	`04`	`X`	`SPA`	`@0 Infección`
C03	`05`	`X`	`FRE`	`@0 Modèle`
C03	`05`	`X`	`ENG`	`@0 Models`
C03	`05`	`X`	`SPA`	`@0 Modelo`
C03	`06`	`X`	`FRE`	`@0 Replication in vitro`
C03	`06`	`X`	`ENG`	`@0 In vitro replication`
C03	`06`	`X`	`SPA`	`@0 Replicación in vitro`
C03	`07`	`X`	`FRE`	`@0 Immunodéficit acquis syndrome @2 NM`
C03	`07`	`X`	`ENG`	`@0 AIDS @2 NM`
C03	`07`	`X`	`SPA`	`@0 Inmunodeficiencia adquirida síndrome @2 NM`
C03	`08`	`X`	`FRE`	`@0 Spécificité`
C03	`08`	`X`	`ENG`	`@0 Specificity`
C03	`08`	`X`	`SPA`	`@0 Especificidad`
C03	`09`	`X`	`FRE`	`@0 Séquence nucléotide`
C03	`09`	`X`	`ENG`	`@0 Nucleotide sequence`
C03	`09`	`X`	`SPA`	`@0 Secuencia nucleótido`
C03	`10`	`X`	`FRE`	`@0 Chimiothérapie`
C03	`10`	`X`	`ENG`	`@0 Chemotherapy`
C03	`10`	`X`	`SPA`	`@0 Quimioterapia`
C03	`11`	`X`	`FRE`	`@0 Traitement`
C03	`11`	`X`	`ENG`	`@0 Treatment`
C03	`11`	`X`	`GER`	`@0 Aufbereiten`
C03	`11`	`X`	`SPA`	`@0 Tratamiento`
C03	`12`	`X`	`FRE`	`@0 In vitro`
C03	`12`	`X`	`ENG`	`@0 In vitro`
C03	`12`	`X`	`SPA`	`@0 In vitro`
C03	`13`	`X`	`FRE`	`@0 Synthèse chimique`
C03	`13`	`X`	`ENG`	`@0 Chemical synthesis`
C03	`13`	`X`	`GER`	`@0 Chemische Synthese`
C03	`13`	`X`	`SPA`	`@0 Síntesis química`
C03	`14`	`X`	`FRE`	`@0 Mécanisme action`
C03	`14`	`X`	`ENG`	`@0 Mechanism of action`
C03	`14`	`X`	`SPA`	`@0 Mecanismo acción`
C03	`15`	`X`	`FRE`	`@0 Lignée MOLT3 @4 INC`
C03	`16`	`X`	`FRE`	`@0 DNA antisens @4 CD`
C03	`16`	`X`	`ENG`	`@0 Antisense DNA @4 CD`
C07	`01`	`X`	`FRE`	`@0 Virus immunodéficience humaine @2 NW`
C07	`01`	`X`	`ENG`	`@0 Human immunodeficiency virus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Human immunodeficiency virus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Lentivirinae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Lentivirinae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Lentivirinae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Retroviridae @2 NW`
C07	`03`	`X`	`ENG`	`@0 Retroviridae @2 NW`
C07	`03`	`X`	`SPA`	`@0 Retroviridae @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virose`
C07	`05`	`X`	`ENG`	`@0 Viral disease`
C07	`05`	`X`	`SPA`	`@0 Virosis`
C07	`06`	`X`	`FRE`	`@0 Immunopathologie`
C07	`06`	`X`	`ENG`	`@0 Immunopathology`
C07	`06`	`X`	`SPA`	`@0 Inmunopatología`
C07	`07`	`X`	`FRE`	`@0 Hémopathie`
C07	`07`	`X`	`ENG`	`@0 Hemopathy`
C07	`07`	`X`	`SPA`	`@0 Hemopatía`
N21				`@1 076`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000109

Links to Exploration step

Pascal:93-0236257

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment</title>
<author><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J." last="Lisziewicz">J. Lisziewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D." last="Sun">D. Sun</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M." last="Klotman">M. Klotman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S." last="Agrawal">S. Agrawal</name>
</author>
<author><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P." last="Zamecnik">P. Zamecnik</name>
</author>
<author><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R." last="Gallo">R. Gallo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">93-0236257</idno>
<date when="1992">1992</date>
<idno type="stanalyst">PASCAL 93-0236257 INIST</idno>
<idno type="RBID">Pascal:93-0236257</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000109</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000105</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment</title>
<author><name sortKey="Lisziewicz, J" sort="Lisziewicz, J" uniqKey="Lisziewicz J" first="J." last="Lisziewicz">J. Lisziewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sun, D" sort="Sun, D" uniqKey="Sun D" first="D." last="Sun">D. Sun</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Klotman, M" sort="Klotman, M" uniqKey="Klotman M" first="M." last="Klotman">M. Klotman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Agrawal, S" sort="Agrawal, S" uniqKey="Agrawal S" first="S." last="Agrawal">S. Agrawal</name>
</author>
<author><name sortKey="Zamecnik, P" sort="Zamecnik, P" uniqKey="Zamecnik P" first="P." last="Zamecnik">P. Zamecnik</name>
</author>
<author><name sortKey="Gallo, R" sort="Gallo, R" uniqKey="Gallo R" first="R." last="Gallo">R. Gallo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Proceedings of the National Academy of Sciences of the United States of America</title>
<title level="j" type="abbreviated">Proc. Natl. Acad. Sci. U. S. A.</title>
<idno type="ISSN">0027-8424</idno>
<imprint><date when="1992">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Proceedings of the National Academy of Sciences of the United States of America</title>
<title level="j" type="abbreviated">Proc. Natl. Acad. Sci. U. S. A.</title>
<idno type="ISSN">0027-8424</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term>
<term>Antisense DNA</term>
<term>Antiviral</term>
<term>Chemical synthesis</term>
<term>Chemotherapy</term>
<term>HIV-1 virus</term>
<term>In vitro</term>
<term>In vitro replication</term>
<term>Infection</term>
<term>Inhibition</term>
<term>Mechanism of action</term>
<term>Models</term>
<term>Nucleotide sequence</term>
<term>Specificity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Virus HIV1</term>
<term>Antiviral</term>
<term>Inhibition</term>
<term>Infection</term>
<term>Modèle</term>
<term>Replication in vitro</term>
<term>Immunodéficit acquis syndrome</term>
<term>Spécificité</term>
<term>Séquence nucléotide</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>In vitro</term>
<term>Synthèse chimique</term>
<term>Mécanisme action</term>
<term>Lignée MOLT3</term>
<term>DNA antisens</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) injection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 μM concentration. Variations in antiviral activity were seen among the different oligonucleotides, invealing an effect of target selection</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0027-8424</s0>
</fA01>
<fA02 i1="01"><s0>PNASA6</s0>
</fA02>
<fA03 i2="1"><s0>Proc. Natl. Acad. Sci. U. S. A.</s0>
</fA03>
<fA05><s2>89</s2>
</fA05>
<fA06><s2>23</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LISZIEWICZ (J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SUN (D.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KLOTMAN (M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>AGRAWAL (S.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ZAMECNIK (P.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GALLO (R.)</s1>
</fA11>
<fA14 i1="01"><s1>NIH, national cancer inst., lab. tumor cell biology</s1>
<s2>Bethesda MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>11209-11213</s1>
</fA20>
<fA21><s1>1992</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>574</s2>
<s5>354000032371390230</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>93-0236257</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Proceedings of the National Academy of Sciences of the United States of America</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We have developed a culture system, simulating in vivo conditions of human immunodeficiency virus type 1 (HIV-1) injection, to evaluate the long-term efficacy of antisense oligonucleotide treatment. Five oligonucleotide phosphorothioates (28-mers), complementary to different regions of HIV-1 RNA, blocked replication of the virus in a sequence-specific manner at 1 μM concentration. Variations in antiviral activity were seen among the different oligonucleotides, invealing an effect of target selection</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Virus HIV1</s0>
<s2>NW</s2>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>HIV-1 virus</s0>
<s2>NW</s2>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>HIV-1 virus</s0>
<s2>NW</s2>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Antiviral</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Antiviral</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Antiviral</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Inhibition</s0>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Inhibition</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Inhibición</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Infection</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Infection</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Infección</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Modèle</s0>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Models</s0>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Modelo</s0>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Replication in vitro</s0>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>In vitro replication</s0>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Replicación in vitro</s0>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Immunodéficit acquis syndrome</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>AIDS</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Inmunodeficiencia adquirida síndrome</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Spécificité</s0>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Specificity</s0>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Especificidad</s0>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Séquence nucléotide</s0>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Nucleotide sequence</s0>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Secuencia nucleótido</s0>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Chimiothérapie</s0>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Chemotherapy</s0>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Quimioterapia</s0>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Traitement</s0>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Treatment</s0>
</fC03>
<fC03 i1="11" i2="X" l="GER"><s0>Aufbereiten</s0>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>In vitro</s0>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>In vitro</s0>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>In vitro</s0>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Synthèse chimique</s0>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Chemical synthesis</s0>
</fC03>
<fC03 i1="13" i2="X" l="GER"><s0>Chemische Synthese</s0>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Síntesis química</s0>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Mécanisme action</s0>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Mechanism of action</s0>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Mecanismo acción</s0>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Lignée MOLT3</s0>
<s4>INC</s4>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>DNA antisens</s0>
<s4>CD</s4>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Antisense DNA</s0>
<s4>CD</s4>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Lentivirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lentivirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Lentivirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Immunopathologie</s0>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Immunopathology</s0>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Inmunopatología</s0>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Hémopathie</s0>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Hemopathy</s0>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Hemopatía</s0>
</fC07>
<fN21><s1>076</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000105 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000105 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:93-0236257
   |texte=   Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment

Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides : an in vitro model for treatment

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri